Loading
Healthcare
8 min read
Areas of Expertise :
Medical Billing, Medical Coding, False Claims Act, Hospital Administration, Healthcare
Published Date:
Last Modified Date:
Jurisdiction:
Federal. Second Circuit
A series of False Claims Act settlements from 2013 to 2015 revealed widespread Medicare billing fraud involving kyphoplasty, a minimally invasive spinal procedure used to treat compression fractures. The U.S. Department of Justice (DOJ) alleged that dozens of hospitals across the country improperly billed Medicare for kyphoplasty as an inpatient procedure, despite clinical guidelines allowing it to be performed safely on an outpatient basis. Between two major settlement waves, 55 hospitals in 2013 paid over $34 million, and 32 more hospitals in 2015 paid over $28 million to resolve allegations. These cases originated from whistleblower lawsuits filed by former Kyphon employees Craig Patrick and Charles Bates, and eventually led to over $180 million in combined settlements, including an earlier $75 million payment by Medtronic Spine LLC, Kyphon’s successor.
The investigations, coordinated by the DOJ, the Department of Health and Human Services Office of Inspector General, and whistleblower law firm Phillips & Cohen LLP, highlighted a national scheme to increase Medicare reimbursements without medical justification. Federal prosecutors emphasized that healthcare fraud of this scale diverts critical public health funds and undermines patient care. The settlements reinforced the government’s ongoing efforts to curb fraudulent billing practices and protect Medicare from unnecessary costs driven by inpatient admissions that were not medically required.
The kyphoplasty False Claims Act litigation began when two former Kyphon Inc. employees, Craig Patrick and Charles Bates, filed a whistleblower lawsuit under the FCA in federal district court in Buffalo, New York. The whistleblowers alleged that Kyphon, a medical device company later acquired by Medtronic, advised hospitals to admit patients for kyphoplasty unnecessarily as inpatients to inflate Medicare billing. This lawsuit triggered federal investigations by the U.S. Department of Justice (DOJ) and the Department of Health and Human Services Office of Inspector General (HHS OIG), laying the groundwork for years of settlements.
Following the whistleblower lawsuit, the DOJ reached a $75 million settlement with Medtronic Spine LLC, the successor to Kyphon. The government alleged that the company promoted inpatient billing practices without medical necessity, encouraging hospitals nationwide to submit inflated Medicare claims. This corporate settlement addressed Kyphon’s alleged role in creating the billing scheme but did not resolve hospital-level liability.
Between 2009 and 2012, the DOJ and HHS OIG broadened their investigation, targeting individual hospitals that followed Kyphon’s billing recommendations. Early settlements included Minnesota hospitals paying $2.28 million in 2009, Indiana and Alabama hospitals paying over $8 million in September 2009, fourteen additional hospitals paying $12 million in 2012. These cases revealed a pattern of hospitals nationwide billing kyphoplasty as an inpatient procedure contrary to clinical standards.
The DOJ’s investigation culminated in a large-scale settlement with 55 hospitals across 21 states, resolving claims of improper kyphoplasty inpatient billing. This marked the largest settlement wave in the case, with hospitals agreeing to correct their billing practices. Federal prosecutors emphasized that these hospitals billed for costlier inpatient services when outpatient treatment was sufficient, draining Medicare funds unnecessarily.
In the final resolution of the nationwide kyphoplasty billing probe, 32 additional hospitals agreed to pay more than $28 million to settle FCA allegations. This settlement, like the previous ones, arose from the original whistleblower lawsuit and government investigation. With this final wave, the total recovery from the kyphoplasty billing fraud cases reached approximately $180 million, including Medtronic’s payment, signaling the close of this multi-year enforcement effort.
Following the final 2015 settlement, no further hospital settlements or litigation developments were officially announced in connection with the kyphoplasty billing fraud allegations. The whistleblower-initiated case concluded as one of the largest coordinated FCA healthcare enforcement actions targeting inpatient billing fraud. The case left a lasting impact on hospital billing compliance and reaffirmed the effectiveness of whistleblower actions in exposing widespread Medicare fraud.
Court:
United States District Court for the Western District of New York
Case Name:
United States ex rel. Bates and Patrick v. Kyphon, Inc.
Healthcare Fraud
Medicare and medicaid
Medical Claims
Medical Utilization
Hospital Finance
A series of False Claims Act settlements from 2013 to 2015 revealed widespread Medicare billing fraud involving kyphoplasty, a minimally invasive spinal procedure used to treat compression fractures. The U.S. Department of Justice (DOJ) alleged that dozens of hospitals across the country improperly billed Medicare for kyphoplasty as an inpatient procedure, despite clinical guidelines allowing it to be performed safely on an outpatient basis. Between two major settlement waves, 55 hospitals in 2013 paid over $34 million, and 32 more hospitals in 2015 paid over $28 million to resolve allegations. These cases originated from whistleblower lawsuits filed by former Kyphon employees Craig Patrick and Charles Bates, and eventually led to over $180 million in combined settlements, including an earlier $75 million payment by Medtronic Spine LLC, Kyphon’s successor.
The investigations, coordinated by the DOJ, the Department of Health and Human Services Office of Inspector General, and whistleblower law firm Phillips & Cohen LLP, highlighted a national scheme to increase Medicare reimbursements without medical justification. Federal prosecutors emphasized that healthcare fraud of this scale diverts critical public health funds and undermines patient care. The settlements reinforced the government’s ongoing efforts to curb fraudulent billing practices and protect Medicare from unnecessary costs driven by inpatient admissions that were not medically required.
The kyphoplasty False Claims Act litigation began when two former Kyphon Inc. employees, Craig Patrick and Charles Bates, filed a whistleblower lawsuit under the FCA in federal district court in Buffalo, New York. The whistleblowers alleged that Kyphon, a medical device company later acquired by Medtronic, advised hospitals to admit patients for kyphoplasty unnecessarily as inpatients to inflate Medicare billing. This lawsuit triggered federal investigations by the U.S. Department of Justice (DOJ) and the Department of Health and Human Services Office of Inspector General (HHS OIG), laying the groundwork for years of settlements.
Following the whistleblower lawsuit, the DOJ reached a $75 million settlement with Medtronic Spine LLC, the successor to Kyphon. The government alleged that the company promoted inpatient billing practices without medical necessity, encouraging hospitals nationwide to submit inflated Medicare claims. This corporate settlement addressed Kyphon’s alleged role in creating the billing scheme but did not resolve hospital-level liability.
Between 2009 and 2012, the DOJ and HHS OIG broadened their investigation, targeting individual hospitals that followed Kyphon’s billing recommendations. Early settlements included Minnesota hospitals paying $2.28 million in 2009, Indiana and Alabama hospitals paying over $8 million in September 2009, fourteen additional hospitals paying $12 million in 2012. These cases revealed a pattern of hospitals nationwide billing kyphoplasty as an inpatient procedure contrary to clinical standards.
The DOJ’s investigation culminated in a large-scale settlement with 55 hospitals across 21 states, resolving claims of improper kyphoplasty inpatient billing. This marked the largest settlement wave in the case, with hospitals agreeing to correct their billing practices. Federal prosecutors emphasized that these hospitals billed for costlier inpatient services when outpatient treatment was sufficient, draining Medicare funds unnecessarily.
In the final resolution of the nationwide kyphoplasty billing probe, 32 additional hospitals agreed to pay more than $28 million to settle FCA allegations. This settlement, like the previous ones, arose from the original whistleblower lawsuit and government investigation. With this final wave, the total recovery from the kyphoplasty billing fraud cases reached approximately $180 million, including Medtronic’s payment, signaling the close of this multi-year enforcement effort.
Following the final 2015 settlement, no further hospital settlements or litigation developments were officially announced in connection with the kyphoplasty billing fraud allegations. The whistleblower-initiated case concluded as one of the largest coordinated FCA healthcare enforcement actions targeting inpatient billing fraud. The case left a lasting impact on hospital billing compliance and reaffirmed the effectiveness of whistleblower actions in exposing widespread Medicare fraud.
Medical Billing and Medical Coding Expert Witnesses
Medical billing and coding expert witnesses are often engaged in False Claims Act litigation to analyze whether Medicare claims comply with billing regulations, procedure codes, and clinical guidelines. In kyphoplasty billing cases, such experts are called in to assess the appropriateness of inpatient versus outpatient billing classifications. These experts help courts and investigators understand complex healthcare billing processes and Medicare reimbursement rules.
Medical Utilization Expert Witness
Medical Utilization experts are often called upon to explain whether a procedure should be performed in an inpatient or outpatient setting based on accepted medical standards. DOJ press releases state that kyphoplasty is safely performed as an outpatient procedure, implying that assessments of clinical appropriateness were central to the government’s case. These experts typically clarify whether medical decisions align with patient care standards rather than reimbursement maximization. Their insights help distinguish between billing fraud and legitimate clinical discretion.
False Claims Act Expert Witness
These legal experts represent relators in False Claims Act cases and contribute specialized knowledge of whistleblower protections and litigation strategy. In this case, Phillips & Cohen attorneys helped uncover and legally pursue the alleged billing fraud. Their expertise lies in applying the FCA’s qui tam provisions to healthcare fraud investigations.
Healthcare Fraud Expert Witness
Healthcare fraud expert witnesses are often engaged to analyze patterns of fraudulent billing and assess whether practices reflect deliberate schemes to defraud Medicare rather than isolated errors. DOJ and HHS OIG described the kyphoplasty cases as coordinated fraudulent billing efforts. These experts typically contribute forensic reviews of billing trends, claim submissions, and provider behavior. Their role complements billing and compliance experts by focusing on the intent and scale of fraudulent activity.
Leverage Whistleblower Qui Tam Actions to Uncover Complex Billing Schemes
The kyphoplasty cases highlight the critical role of whistleblowers in exposing healthcare fraud under the False Claims Act. Attorneys representing whistleblowers should build strong pre-filing investigations and collaborate closely with government agencies. Effective qui tam cases can drive large-scale industry compliance and recover substantial public funds.
Emphasize Medical Necessity in Challenging Fraudulent Billing Practices
A core legal argument in these settlements was the clinical appropriateness of inpatient versus outpatient procedures. Attorneys litigating healthcare fraud cases should work with medical necessity experts to differentiate between billing errors and systemic fraud. DOJ’s position on kyphoplasty demonstrates that unjustified inpatient admissions are a clear target for FCA enforcement.
Utilize Healthcare Compliance Standards to Prove Systemic Violations
The government’s case against hospitals rested on evidence that billing practices deviated from Medicare compliance frameworks. Attorneys should investigate institutional billing protocols, CMS guidelines, and audit results to demonstrate whether non-compliance was isolated or systemic. Establishing a pattern of violations strengthens FCA liability claims.
Coordinate Multi-State Enforcement for Broader Litigation Impact
The DOJ structured the kyphoplasty settlements across multiple states and hospital systems, maximizing enforcement reach. Attorneys involved in FCA cases may consider parallel investigations or coordinated litigation strategies to address nationwide billing practices. Multi-district investigations can increase settlement leverage and create industry-wide deterrence.
Target False Inpatient Billing as a High-Risk FCA Violation Area
Kyphoplasty litigation confirms that upcoding outpatient procedures as inpatient admissions remains a top priority for Medicare fraud enforcement. Attorneys advising healthcare providers should conduct proactive audits of inpatient billing categories prone to scrutiny. Preventive compliance measures can mitigate FCA risks and reduce exposure to whistleblower claims.
The kyphoplasty Medicare billing fraud settlements represent one of the most significant False Claims Act enforcement efforts targeting improper inpatient billing practices in U.S. healthcare. Sparked by a whistleblower lawsuit and followed by coordinated investigations from the DOJ and HHS OIG, the case revealed how widespread misuse of inpatient billing codes for outpatient procedures could lead to substantial financial recoveries. With over $180 million in total settlements, including Medtronic’s corporate payment and multi-state hospital agreements, the litigation reinforced the critical role of whistleblowers and compliance monitoring in uncovering fraudulent billing schemes.
Beyond the specific hospitals and procedures involved, this case highlights broader trends in healthcare fraud enforcement. Federal agencies continue to prioritize cases where billing practices reflect systemic disregard for Medicare regulations and clinical guidelines, especially when hospitals seek higher reimbursements through improper inpatient admissions. For healthcare providers, legal counsel, and compliance professionals, the kyphoplasty case serves as a reminder that maintaining billing integrity is essential to avoid False Claims Act liability and government investigations.
What was the kyphoplasty Medicare fraud case about?
The kyphoplasty Medicare fraud case involved hospitals billing Medicare for kyphoplasty procedures as inpatient admissions instead of outpatient services. The U.S. Department of Justice alleged this resulted in inflated Medicare reimbursements without medical necessity. Multiple hospitals settled False Claims Act allegations to resolve the charges.
Who filed the whistleblower lawsuit in the kyphoplasty fraud case?
The whistleblower lawsuit was filed by Craig Patrick and Charles Bates, former employees of Kyphon Inc. They alleged that hospitals and Medtronic promoted improper billing practices for kyphoplasty procedures. Their lawsuit triggered federal investigations and multiple healthcare fraud settlements.
How much money was recovered in the kyphoplasty Medicare fraud settlements?
The combined settlements in the kyphoplasty Medicare fraud case totaled approximately $180 million. This included a $75 million corporate settlement with Medtronic Spine LLC and multiple hospital settlements from 2009 to 2015. The recoveries reflect the government’s focus on protecting Medicare funds from fraudulent billing.
Why was kyphoplasty considered outpatient but billed as inpatient?
Kyphoplasty is a minimally invasive procedure that clinical guidelines state can be safely performed on an outpatient basis. Hospitals allegedly billed the procedure as inpatient to receive higher Medicare payments. The government argued this practice resulted in false claims submitted to Medicare.
When did the kyphoplasty Medicare fraud settlements occur?
The settlements occurred over several years, with key resolutions in 2009, 2013, and 2015. Medtronic’s corporate settlement happened in 2008, and major hospital settlements followed in waves. The final large group of hospitals settled in December 2015, concluding the main enforcement actions.
Medical Billing and Medical Coding Expert Witnesses
Medical billing and coding expert witnesses are often engaged in False Claims Act litigation to analyze whether Medicare claims comply with billing regulations, procedure codes, and clinical guidelines. In kyphoplasty billing cases, such experts are called in to assess the appropriateness of inpatient versus outpatient billing classifications. These experts help courts and investigators understand complex healthcare billing processes and Medicare reimbursement rules.
Medical Utilization Expert Witness
Medical Utilization experts are often called upon to explain whether a procedure should be performed in an inpatient or outpatient setting based on accepted medical standards. DOJ press releases state that kyphoplasty is safely performed as an outpatient procedure, implying that assessments of clinical appropriateness were central to the government’s case. These experts typically clarify whether medical decisions align with patient care standards rather than reimbursement maximization. Their insights help distinguish between billing fraud and legitimate clinical discretion.
False Claims Act Expert Witness
These legal experts represent relators in False Claims Act cases and contribute specialized knowledge of whistleblower protections and litigation strategy. In this case, Phillips & Cohen attorneys helped uncover and legally pursue the alleged billing fraud. Their expertise lies in applying the FCA’s qui tam provisions to healthcare fraud investigations.
Healthcare Fraud Expert Witness
Healthcare fraud expert witnesses are often engaged to analyze patterns of fraudulent billing and assess whether practices reflect deliberate schemes to defraud Medicare rather than isolated errors. DOJ and HHS OIG described the kyphoplasty cases as coordinated fraudulent billing efforts. These experts typically contribute forensic reviews of billing trends, claim submissions, and provider behavior. Their role complements billing and compliance experts by focusing on the intent and scale of fraudulent activity.
Leverage Whistleblower Qui Tam Actions to Uncover Complex Billing Schemes
The kyphoplasty cases highlight the critical role of whistleblowers in exposing healthcare fraud under the False Claims Act. Attorneys representing whistleblowers should build strong pre-filing investigations and collaborate closely with government agencies. Effective qui tam cases can drive large-scale industry compliance and recover substantial public funds.
Emphasize Medical Necessity in Challenging Fraudulent Billing Practices
A core legal argument in these settlements was the clinical appropriateness of inpatient versus outpatient procedures. Attorneys litigating healthcare fraud cases should work with medical necessity experts to differentiate between billing errors and systemic fraud. DOJ’s position on kyphoplasty demonstrates that unjustified inpatient admissions are a clear target for FCA enforcement.
Utilize Healthcare Compliance Standards to Prove Systemic Violations
The government’s case against hospitals rested on evidence that billing practices deviated from Medicare compliance frameworks. Attorneys should investigate institutional billing protocols, CMS guidelines, and audit results to demonstrate whether non-compliance was isolated or systemic. Establishing a pattern of violations strengthens FCA liability claims.
Coordinate Multi-State Enforcement for Broader Litigation Impact
The DOJ structured the kyphoplasty settlements across multiple states and hospital systems, maximizing enforcement reach. Attorneys involved in FCA cases may consider parallel investigations or coordinated litigation strategies to address nationwide billing practices. Multi-district investigations can increase settlement leverage and create industry-wide deterrence.
Target False Inpatient Billing as a High-Risk FCA Violation Area
Kyphoplasty litigation confirms that upcoding outpatient procedures as inpatient admissions remains a top priority for Medicare fraud enforcement. Attorneys advising healthcare providers should conduct proactive audits of inpatient billing categories prone to scrutiny. Preventive compliance measures can mitigate FCA risks and reduce exposure to whistleblower claims.
The kyphoplasty Medicare billing fraud settlements represent one of the most significant False Claims Act enforcement efforts targeting improper inpatient billing practices in U.S. healthcare. Sparked by a whistleblower lawsuit and followed by coordinated investigations from the DOJ and HHS OIG, the case revealed how widespread misuse of inpatient billing codes for outpatient procedures could lead to substantial financial recoveries. With over $180 million in total settlements, including Medtronic’s corporate payment and multi-state hospital agreements, the litigation reinforced the critical role of whistleblowers and compliance monitoring in uncovering fraudulent billing schemes.
Beyond the specific hospitals and procedures involved, this case highlights broader trends in healthcare fraud enforcement. Federal agencies continue to prioritize cases where billing practices reflect systemic disregard for Medicare regulations and clinical guidelines, especially when hospitals seek higher reimbursements through improper inpatient admissions. For healthcare providers, legal counsel, and compliance professionals, the kyphoplasty case serves as a reminder that maintaining billing integrity is essential to avoid False Claims Act liability and government investigations.
What was the kyphoplasty Medicare fraud case about?
The kyphoplasty Medicare fraud case involved hospitals billing Medicare for kyphoplasty procedures as inpatient admissions instead of outpatient services. The U.S. Department of Justice alleged this resulted in inflated Medicare reimbursements without medical necessity. Multiple hospitals settled False Claims Act allegations to resolve the charges.
Who filed the whistleblower lawsuit in the kyphoplasty fraud case?
The whistleblower lawsuit was filed by Craig Patrick and Charles Bates, former employees of Kyphon Inc. They alleged that hospitals and Medtronic promoted improper billing practices for kyphoplasty procedures. Their lawsuit triggered federal investigations and multiple healthcare fraud settlements.
How much money was recovered in the kyphoplasty Medicare fraud settlements?
The combined settlements in the kyphoplasty Medicare fraud case totaled approximately $180 million. This included a $75 million corporate settlement with Medtronic Spine LLC and multiple hospital settlements from 2009 to 2015. The recoveries reflect the government’s focus on protecting Medicare funds from fraudulent billing.
Why was kyphoplasty considered outpatient but billed as inpatient?
Kyphoplasty is a minimally invasive procedure that clinical guidelines state can be safely performed on an outpatient basis. Hospitals allegedly billed the procedure as inpatient to receive higher Medicare payments. The government argued this practice resulted in false claims submitted to Medicare.
When did the kyphoplasty Medicare fraud settlements occur?
The settlements occurred over several years, with key resolutions in 2009, 2013, and 2015. Medtronic’s corporate settlement happened in 2008, and major hospital settlements followed in waves. The final large group of hospitals settled in December 2015, concluding the main enforcement actions.
What federal agencies investigated the kyphoplasty Medicare billing fraud?
The U.S. Department of Justice (DOJ) and the Department of Health and Human Services Office of Inspector General (HHS OIG) led the investigations. These agencies reviewed hospital billing practices for Medicare compliance and medical necessity. Their coordinated efforts resulted in multi-state False Claims Act settlements.
Healthcare Fraud
Medicare and medicaid
Medical Claims
Medical Utilization
Hospital Finance
Medical Devices, +4
Healthcare
Healthcare, +4
Healthcare
What federal agencies investigated the kyphoplasty Medicare billing fraud?
The U.S. Department of Justice (DOJ) and the Department of Health and Human Services Office of Inspector General (HHS OIG) led the investigations. These agencies reviewed hospital billing practices for Medicare compliance and medical necessity. Their coordinated efforts resulted in multi-state False Claims Act settlements.